<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="40" ids="35498">Diuretics</z:chebi> (<z:chebi fb="0" ids="50264">thiazides</z:chebi>, loop <z:chebi fb="40" ids="35498">diuretics</z:chebi>) are established as treatments of common diseases: arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In aging societies, their prevalence sharply rises with age </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, <z:chebi fb="40" ids="35498">diuretic</z:chebi> efficacy and safety need to be considered in the elderly as main consumers </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="40" ids="35498">Diuretics</z:chebi> expose several disadvantages with particular relevance for the elderly </plain></SENT>
<SENT sid="4" pm="."><plain>The most acknowledged side effects concern electrolyte disturbances </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002900'>Hypokalemia</z:hpo> (up to 8%) may not only precipitate <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and related <z:hpo ids='HP_0001699'>sudden death</z:hpo> but also <z:e sem="disease" ids="C0235704" disease_type="Disease or Syndrome" abbrv="">adynamia</z:e> by <z:hpo ids='HP_0001324'>muscular weakness</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002902'>Hyponatremia</z:hpo> (up to 17%) may contribute to <z:hpo ids='HP_0001289'>confusion</z:hpo>, <z:e sem="disease" ids="C0011206" disease_type="Mental or Behavioral Dysfunction" abbrv="">delirium</z:e>, and irreversible brain damage adding to age-related <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="50264">Thiazides</z:chebi> are the <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> with the strongest diabetogenic activity </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0001635'>heart failure</z:hpo> treatment, overdosing of <z:chebi fb="40" ids="35498">diuretics</z:chebi> is common, as doses often reflect requirements for <z:hpo ids='HP_0011009'>acute</z:hpo> recompensation, which is two- to threefold the requirement of that in maintenance therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Trial data demonstrate a positive correlation between mortality and <z:chebi fb="40" ids="35498">diuretic</z:chebi> use/dose, which may also be related to volume contraction, related <z:chebi fb="2" ids="35457">ACE-inhibitor</z:chebi> intolerance, <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>, and venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Combining loop and <z:chebi fb="0" ids="50264">thiazide</z:chebi> <z:chebi fb="40" ids="35498">diuretics</z:chebi> may be indicated for severe cardiac or <z:hpo ids='HP_0000083'>renal failure</z:hpo>, but it is also excessively used in less severe stages, causing an even more severe threat to patients; <z:chebi fb="0" ids="50264">thiazides</z:chebi> are often added unintentionally if overlooked in combination pills </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="40" ids="35498">Diuretics</z:chebi> may be used to treat peripheral "<z:hpo ids='HP_0000969'>edema</z:hpo>" in <z:mp ids='MP_0001261'>obese</z:mp> patients, patients on calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi>, or those with venous <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Here they are not indicated and may even induce <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>In statistics on adverse drug reactions leading to hospitalization, <z:chebi fb="40" ids="35498">diuretics</z:chebi> are among the 5 leading drug classes </plain></SENT>
<SENT sid="14" pm="."><plain>Misleading interpretations of clinical trials and their low cost have pushed them into the front position of <z:hpo ids='HP_0000822'>hypertension</z:hpo> treatment </plain></SENT>
<SENT sid="15" pm="."><plain>Here, side effects, including the urge of voiding, lead to the lowest adherence rate among first-line <z:chebi fb="0" ids="35674">antihypertensives</z:chebi> </plain></SENT>
<SENT sid="16" pm="."><plain>It is proposed to term the syndrome of inappropriate <z:chebi fb="40" ids="35498">diuretic</z:chebi> application "morbus diureticus." ItÂ should be diagnosed by history taking, force assessment (timed-up-and-go, chair-rise tests), clinical hydration assessment, and laboratory tests (electrolytes, <z:chebi fb="0" ids="16737">creatinine</z:chebi>) </plain></SENT>
<SENT sid="17" pm="."><plain>In <z:hpo ids='HP_0001635'>heart failure</z:hpo>, dose reductions/step-down from loop to <z:chebi fb="0" ids="50264">thiazide</z:chebi> <z:chebi fb="40" ids="35498">diuretics</z:chebi> should be tested routinely at 3- to 6-month intervals </plain></SENT>
<SENT sid="18" pm="."><plain>In <z:hpo ids='HP_0000822'>hypertension</z:hpo> treatment, <z:chebi fb="40" ids="35498">diuretics</z:chebi> should be third in line if control by <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors and long-acting <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi> is insufficient </plain></SENT>
<SENT sid="19" pm="."><plain>If symptoms improve after <z:chebi fb="40" ids="35498">diuretic</z:chebi> step-down (including improved tolerance to <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors or renal function), this diagnosis may also be made "ex juvantibus." </plain></SENT>
</text></document>